OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
CN Stock MarketDetailed Quotes
688252 Jadard Technology Inc.
- 25.98
- +0.15+0.58%
Market Closed Apr 1 15:00 CST
10.63BMarket Cap38.66P/E (TTM)
27.25High25.78Low120.07KlotVolume25.83Open25.83Pre Close317.72MTurnover6.59%Turnover Ratio38.66P/E (Static)409.02MShares30.4952wk High4.87P/B4.74BFloat Cap10.8252wk Low31.00Limit Up182.34MShs Float30.49Historical High20.66Limit Down5.69%Amplitude9.37Historical Low0.06Dividend TTM26.46Avg Price54.44KlotAsk0.22%Div YieldTTM100Lot Size59.54KlotBid
Jadard Technology Inc. Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 73.88%2.1B | 79.57%1.48B | 67.74%842.81M | 46.07%345.29M | 0.88%1.21B | -12.38%826.33M | -22.57%502.46M | -18.47%236.39M | 7.40%1.2B | 20.72%943.13M |
| Operating revenue | 73.88%2.1B | 79.57%1.48B | 67.74%842.81M | 46.07%345.29M | 0.88%1.21B | -12.38%826.33M | -22.57%502.46M | -18.47%236.39M | 7.40%1.2B | 20.72%943.13M |
| Total operating cost | 66.31%1.84B | 71.40%1.31B | 62.26%753.97M | 43.19%318.56M | 4.85%1.11B | -2.37%762.81M | -6.72%464.67M | 0.00%222.47M | 44.32%1.06B | 56.56%781.33M |
| Operating cost | 70.83%1.65B | 76.52%1.17B | 68.63%668.71M | 47.63%277.72M | 11.29%967.03M | 2.67%660.88M | -3.42%396.56M | 8.72%188.12M | 59.49%868.9M | 74.57%643.68M |
| Operating tax surcharges | 91.90%2.94M | 207.84%2.09M | 239.51%1.07M | 158.42%359.34K | -40.27%1.53M | -70.16%678.37K | -81.22%315.68K | -85.32%139.05K | -8.60%2.56M | 39.59%2.27M |
| Operating expense | 82.40%41.63M | 95.62%30.43M | 81.91%18.41M | 48.48%7.24M | -19.57%22.82M | -28.28%15.56M | -26.24%10.12M | -39.28%4.88M | 4.85%28.38M | 9.30%21.69M |
| Administration expense | 27.03%26.34M | 39.53%21.31M | 33.39%13.57M | 31.61%6.7M | -35.26%20.74M | -31.74%15.27M | -30.91%10.17M | -28.27%5.09M | -2.27%32.03M | -3.66%22.38M |
| Financial expense | -16.41%-55.6M | -22.05%-37.53M | -42.19%-26.55M | -56.96%-11.93M | -94.14%-47.76M | -112.12%-30.75M | -60.43%-18.67M | -531.02%-7.6M | -291.54%-24.6M | -157.07%-14.49M |
| Research and development | 22.20%175.75M | 23.16%124.59M | 19.01%78.75M | 20.79%38.47M | -3.88%143.82M | -4.39%101.16M | -4.20%66.17M | -7.88%31.84M | 14.07%149.63M | 15.92%105.81M |
| Credit Impairment Loss | 226.18%312.11K | 323.94%307.68K | 21.60%92.46K | 44.76%-175.07K | -110.07%-247.34K | -97.00%72.58K | -96.54%76.04K | -568.68%-316.92K | 208.19%2.46M | 309.83%2.42M |
| Asset Impairment Loss | -65.05%-9.84M | -982.16%-8.49M | -2,505.45%-4.82M | -94.68%-1.56M | 68.21%-5.96M | 70.16%-784.72K | 90.21%-185.11K | 50.13%-799.16K | -1,991.21%-18.75M | -231.12%-2.63M |
| Other net revenue | ||||||||||
| Fair value change income | --83.18K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Asset deal income | 251.59%51.61K | ---- | ---- | ---- | -680.24%-34.05K | ---55.49K | ---34.4K | --21.44K | --5.87K | ---- |
| Other revenue | 91.80%41.32M | 211.11%35.32M | 153.65%22.3M | 2,386.57%10.68M | 317.83%21.54M | 369.01%11.35M | 868.40%8.79M | -47.88%429.64K | -44.34%5.16M | -73.55%2.42M |
| Operating profit | 150.77%290.9M | 174.65%203.53M | 129.15%106.41M | 169.33%35.69M | -10.96%116M | -54.82%74.11M | -69.45%46.44M | -80.15%13.25M | -66.55%130.28M | -43.32%164.01M |
| Add:Non operating Income | --858.88K | --663.77K | --581.82K | --260.36K | ---- | ---- | ---- | ---- | 4,716.20%307.78K | 147.90%15.84K |
| Less:Non operating expense | -93.89%12.16K | -17.84%11.38K | --3.91K | ---- | -15.73%199.03K | -71.91%13.85K | ---- | ---- | -88.19%236.19K | --49.3K |
| Total profit | 151.93%291.75M | 175.58%204.18M | 130.39%106.99M | 171.29%35.95M | -11.16%115.8M | -54.81%74.09M | -69.45%46.44M | -80.15%13.25M | -66.36%130.36M | -43.34%163.97M |
| Less:Income tax cost | 468.08%16.87M | 1,740.97%12.19M | 3,209.09%6M | 30.47%3.42M | 420.45%2.97M | -109.91%-742.77K | -102.83%-193.04K | -73.07%2.62M | -99.02%570.46K | -81.90%7.5M |
| Net profit | 143.61%274.88M | 156.55%191.99M | 116.57%100.98M | 206.02%32.53M | -13.06%112.84M | -52.18%74.83M | -67.89%46.63M | -81.36%10.63M | -60.59%129.78M | -36.90%156.48M |
| Net profit from continuing operation | 143.61%274.88M | 156.55%191.99M | 116.57%100.98M | 206.02%32.53M | -13.06%112.84M | -52.18%74.83M | --46.63M | -81.36%10.63M | -60.59%129.78M | -36.90%156.48M |
| Net profit of parent company owners | 143.61%274.88M | 156.55%191.99M | 116.57%100.98M | 206.02%32.53M | -13.06%112.84M | -52.18%74.83M | -67.89%46.63M | -81.36%10.63M | -60.59%129.78M | -36.90%156.48M |
| Earning per share | ||||||||||
| Basic earning per share | 142.86%0.68 | 161.11%0.47 | 127.27%0.25 | 166.67%0.08 | -20.00%0.28 | -58.14%0.18 | -72.50%0.11 | -81.25%0.03 | -61.11%0.35 | -36.76%0.43 |
| Diluted earning per share | 148.15%0.67 | 161.11%0.47 | 127.27%0.25 | 166.67%0.08 | -22.86%0.27 | -58.14%0.18 | -72.50%0.11 | -81.25%0.03 | -61.11%0.35 | -36.76%0.43 |
| Other composite income | -69.06%1.96M | -106.88%-573.81K | -67.76%2.28M | 156.69%2.11M | 217.76%6.34M | -2.85%8.34M | 180.71%7.08M | -2,284.72%-3.73M | 153.27%2M | 732.16%8.59M |
| Other composite income of parent company owners | -69.06%1.96M | -106.88%-573.81K | -67.76%2.28M | 156.69%2.11M | 217.76%6.34M | -2.85%8.34M | 180.71%7.08M | ---3.73M | 153.27%2M | 732.16%8.59M |
| Total composite income | 132.29%276.84M | 130.13%191.42M | 92.26%103.27M | 401.93%34.64M | -9.56%119.18M | -49.61%83.18M | -63.64%53.71M | -87.87%6.9M | -59.52%131.78M | -33.07%165.06M |
| Total composite income of parent company owners | 132.29%276.84M | 130.13%191.42M | 92.26%103.27M | 401.93%34.64M | -9.56%119.18M | -49.61%83.18M | -63.64%53.71M | -87.87%6.9M | -59.52%131.78M | -33.07%165.06M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | -- | Unqualified opinion | -- | -- | -- | -- | -- |
| Auditor | -- | -- | -- | -- | Dahua Certified Public Accountants (Special General Partnership) | -- | -- | -- | Dahua Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.